ABBOTT PARK, Ill., May 18 /PRNewswire-FirstCall/ -- Abbott today announced that it will present new data from its SPIRIT family of clinical trials studying the XIENCE(TM) V Everolimus Eluting Coronary Stent System, and the ABSORB trial of the world’s first fully bioabsorbable drug-eluting coronary stent, at the EuroPCR meeting May 22-25 in Barcelona, Spain. Abbott also will launch The Crossroads Institute at the meeting, an educational institute dedicated to advancing cardiac and vascular medical education to improve patient care.
Late-breaking data presentations from Abbott at EuroPCR 2007 include three-year data from its SPIRIT FIRST trial; a meta-analysis of SPIRIT II and SPIRIT III data that compares the performance of the XIENCE V system to the TAXUS(R) Paclitaxel-Eluting Coronary Stent System; and nine-month data on ABSORB.
Following are Abbott’s late-breaking presentations at EuroPCR: ABSORB Nine-Month Data Tuesday, May 22, 5:55 p.m. Central Europe Time (11:55 a.m. EDT) Room 1 (Main Arena), Barcelona International Convention Center Dariusz Dudek, M.D., of Jagiellonian University, Krakow, Poland, will present nine-month data from the ABSORB clinical trial evaluating the overall safety and performance of the world’s first fully bioabsorbable drug-eluting coronary stent for the treatment of coronary artery disease. Abbott’s bioabsorbable drug-eluting coronary stent is currently an investigational device. SPIRIT FIRST Three-Year Data, SPIRIT II and SPIRIT III Meta-Analysis Tuesday, May 22, 6:17 p.m. Central Europe Time (12:17 p.m. EDT) Room 1 (Main Arena), Barcelona International Convention Center Gregg W. Stone, M.D., of Columbia University Medical Center and the Cardiovascular Research Foundation, New York, will present three-year results from the SPIRIT FIRST trial, and a retrospective meta-analysis of the SPIRIT II and SPIRIT III trials. The SPIRIT family of clinical trials is designed to study the safety and performance of the XIENCE V Everolimus Eluting Coronary Stent System in treating patients with coronary artery disease.
XIENCE V was launched in Europe and Asia Pacific in 2006. XIENCE V is currently an investigational device in the United States and Japan. Results from the SPIRIT III trial are intended to support U.S. FDA approval of the XIENCE V Stent System and Ministry of Health and Welfare approval in Japan. Abbott expects to submit XIENCE V for United States approval in the second quarter of 2007.
XIENCE V is a trademark of Abbott. TAXUS is a trademark of Boston Scientific. The SPIRIT Clinical Program is sponsored by Abbott.
Premier Presentation by Crossroads Institute Faculty: Tackling Tough Lesions: The Experts’ Approach Tuesday, May 22, 3 p.m. Central Europe Time (9 a.m. EDT), Room 7 Leading researchers and physicians will discuss the use of imaging tools in the clinical decision-making process. The Crossroads Institute is funded by Abbott.
About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world’s leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.
About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.
Abbott’s news releases and other information are available on the company’s Web site at http://www.abbott.com.
Abbott
CONTACT: Media, Karin Bauer Aranaz, +1-408-845-3887, +1-650-868-2999, orFinancial, Tina Ventura, +1-847-935-9390, both of Abbott
Web site: http://www.abbott.com/
